Repligen to Present at 37th Annual J.P. Morgan Healthcare Conference
January 03 2019 - 01:26PM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that it
will present at the 37th Annual J.P. Morgan Healthcare conference
being held January 7-10 at the Westin St. Francis in San
Francisco. Tony J. Hunt, President and Chief Executive
Officer, will make a formal presentation on Tuesday, January 8, at
5:30 p.m. PST. A live webcast of the presentation will be
accessible through the Investor Events section of the Company’s
website, and will be available for replay for a limited period of
time following the conference event.
About Repligen
Corporation Repligen Corporation (NASDAQ:RGEN) is a
bioprocessing-focused company that develops and commercializes
highly innovative products that deliver cost and process
efficiencies to biological drug manufacturers worldwide. Our
portfolio includes protein products (Protein A affinity ligands,
cell culture growth factors), chromatography products (OPUS®
pre-packed columns, chromatography resins, ELISA kits) and
filtration products (XCell™ ATF systems, SIUS™ flat sheet TFF
cassettes, and Spectrum KrosFlo™ hollow fiber TFF cartridges and
systems). The Protein A ligands and growth factor products that we
produce are key components of Protein A affinity resins and cell
culture media, respectively. Protein A affinity resins are the
industry standard for downstream separation and purification of
monoclonal antibody-based therapeutics. Growth factors are used in
upstream processes to accelerate cell growth and productivity. Our
innovative line of OPUS® chromatography columns, used in downstream
processes for bench-scale to commercial-scale purification needs,
are delivered pre-packed and customized to our customers choice of
resin and packed bed height. Our XCell™ ATF Systems, available in
stainless steel and single-use configurations, continuously
eliminate waste from a bioreactor to concentrate cells and
significantly increase productivity in upstream processes.
Single-use SIUS™ TFF cassettes and hardware are used for biologic
drug concentration in downstream filtration processes. Spectrum
KrosFlo™ TFF cartridges and systems are used in both upstream and
downstream filtration processes. Repligen’s corporate headquarters
are in Waltham, MA (USA), with additional administrative and
manufacturing operations at locations including Shrewsbury, MA,
Rancho Dominguez, CA, Lund, Sweden and Ravensburg, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Source: Repligen Corporation Sondra Newman Senior Director
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024